View Filing Data

Document and Entity Information Document - shares	3 Months Ended
Document and Entity Information Document - shares	Mar. 31, 2013	May 03, 2013
Entity Information [Line Items]
Entity Registrant Name	BioScrip, Inc.
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		67,529,494

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2013	Dec. 31, 2012
Current assets
Cash and cash equivalents	$ 0	$ 62,101
Receivables, less allowance for doubtful accounts	158,127	129,103
Inventory	22,819	34,034
Prepaid expenses and other current assets	9,081	10,189
Total current assets	190,027	235,427
Property and equipment, net	27,767	23,721
Goodwill	414,234	350,810
Intangible assets, net	19,364	17,446
Deferred financing costs	2,522	2,877
Investments in and advances to unconsolidated affiliate	10,415	10,042
Other non-current assets	1,385	2,053
Total assets	665,714	642,376
Current liabilities
Current portion of long-term debt	27,992	953
Accounts payable	32,108	34,438
Claims payable	7,599	7,411
Amounts due to plan sponsors	16,303	18,173
Accrued interest	11,575	5,803
Accrued expenses and other current liabilities	37,580	41,491
Total current liabilities	133,157	108,269
Long-term debt, net of current portion	225,372	225,426
Deferred taxes	10,748	10,291
Other non-current liabilities	8,971	4,981
Total liabilities	378,248	348,967
Stockholders' equity
Preferred stock	0	0
Common stock	6	6
Treasury stock	(10,311)	(10,311)
Additional paid-in capital	390,983	388,798
Accumulated deficit	(93,212)	(85,084)
Total stockholders' equity	287,466	293,409
Total liabilities and stockholders' equity	$ 665,714	$ 642,376

CONSOLIDATED BALANCE SHEETS Balance Sheet Parenthetical - USD ($)	Mar. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts Receivable, Current	$ 21,482,000	$ 22,212,000
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	125,000,000	125,000,000
Common Stock, Shares, Issued	59,695,646	59,600,713
Common Stock, Shares, Outstanding	57,113,126	57,026,957
Treasury Stock, Shares	2,582,520	2,582,520

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Product revenue	$ 150,024	$ 106,803
Service revenue	49,047	48,830
Total revenue	199,071	155,633
Cost of product revenue	105,533	72,326
Cost of service revenue	30,301	29,785
Total cost of revenue	135,834	102,111
Gross profit	63,237	53,522
Selling, general and administrative expenses	52,791	44,575
Bad debt expense	3,397	3,465
Acquisition and integration expenses	4,623	172
Restructuring and other expenses	1,278	387
Amortization of intangibles	2,082	879
Income from continuing operations	(934)	4,044
Interest expense, net	6,478	6,569
Loss from continuing operations before income taxes	(7,412)	(2,525)
Income tax expense (benefit)	58	(502)
Loss from continuing operations, net of income taxes	(7,470)	(2,023)
Loss from discontinued operations, net of income taxes	(658)	(680)
Net loss	$ (8,128)	$ (2,703)
Income (loss) per common share
Basic loss from continuing operations	$ (0.13)	$ (0.04)
Basic loss from discontinued operations	(0.01)	(0.01)
Basic loss	(0.14)	(0.05)
Diluted loss from continuing operations	(0.13)	(0.04)
Diluted loss from discontinued operations	(0.01)	(0.01)
Diluted loss	$ (0.14)	$ (0.05)
Weighted average common shares outstanding
Basic	57,047	55,307
Diluted	57,047	55,307

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash flows from operating activities:
Net loss	$ (8,128)	$ (2,703)
Loss from discontinued operations, net of income taxes	(658)	(680)
Loss from continuing operations, net of income taxes	(7,470)	(2,023)
Adjustments to reconcile loss from continuing operations, net of income taxes to net cash provided by (used in) operating activities:
Depreciation	2,459	1,931
Amortization of intangibles	2,082	879
Change in deferred income tax	457	(300)
Amortization of deferred financing costs	356	284
Compensation under stock-based compensation plans	1,973	966
Loss on disposal of fixed assets	13	23
Changes in assets and liabilities, net of amounts acquired in acquisitions:
Receivables, net of bad debt expense	(16,526)	(16,761)
Inventory	13,199	4,215
Prepaid expenses and other assets	2,487	4,238
Accounts payable	(2,822)	5,587
Claims payable	187	(6,598)
Amounts due to plan sponsors	(4,140)	(874)
Accrued expenses and other liabilities	(4,445)	4,557
Net cash used in operating activities from continuing operations	(12,190)	(3,876)
Net cash (used on) provided by operating activities from discontinued operations	(658)	6,401
Net cash (used in) provided by operating activities	(12,848)	2,525
Cash flows from investing activities:
Purchases of property and equipment, net	(3,655)	(1,547)
Cash consideration paid for acquisitions, net of cash acquired	(72,325)	0
Cash consideration paid to DS Pharmacy	0	(2,935)
Cash consideration paid for unconsolidated affiliate, net of cash acquired	(900)	0
Net cash used in investing activities from continuing operations	(76,880)	(4,482)
Net cash provided by investing activities from discontinued operations	0	2,741
Net cash used in investing activities	(76,880)	(1,741)
Cash flows from financing activities:
Borrowings on line of credit	214,145	481,151
Repayments on line of credit	(187,092)	(483,224)
Repayments of capital leases	(68)	(35)
Net proceeds from exercise of employee stock compensation plans	642	1,324
Net cash provided by (used in) financing activities	27,627	(784)
Net change in cash and cash equivalents	(62,101)	0
Cash and cash equivalents - beginning of period	62,101	0
Cash and cash equivalents - end of period	0	0
DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	322	1,241
Cash paid during the period for income taxes	(6)	197
DISCLOSURE OF NON-CASH TRANSACTIONS:
Capital lease obligations incurred to acquire property and equipment	$ 0	$ 20

BASIS OF PRESENTATION	3 Months Ended
BASIS OF PRESENTATION	Mar. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	BASIS OF PRESENTATION These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2012 (the “Form 10-K”) filed with the U.S. Securities and Exchange Commission. These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the full year ended December 31, 2013. The accounting policies followed for interim financial reporting are similar to those disclosed in Note 2 of the Audited Consolidated Financial Statements included in the Form 10-K. The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the consolidation. In accordance with the applicable accounting guidance for the consolidation of variable interest entities, the Company analyzes its variable interests to determine if an entity in which it has a variable interest is a variable interest entity. The Company's analysis includes both quantitative and qualitative reviews. The Company bases its quantitative analysis on the forecasted cash flows of the entity, and its qualitative analysis on its review of the design of the entity, its organizational structure, including decision-making ability, and relevant financial agreements. The Company also uses its qualitative analysis to determine if it must consolidate a variable interest entity as its primary beneficiary. At March 31, 2013, the Company had an affiliate equity investment in a variable interest entity that has developed a platform that facilitates the flow, management and sharing of vital health and medical information with stakeholders across the healthcare ecosystem. The Company concluded that the entity is a variable interest entity because the equity investment at risk is not sufficient to permit the entity to finance its activities without additional support from other parties. The Company determined that it is not the primary beneficiary as power to direct the activities that most significantly impact economic performance of the entity is held by another stakeholder, and therefore does not consolidate the entity. The Company's investment in this variable interest entity is recorded in the investments in and advances to unconsolidated affiliate line on the accompanying Consolidated Balance Sheets using the equity method of accounting. Subsequent to March 31, 2013. the Company disposed of this investment. Refer to Note 16 for more information. Acquisition and integration expenses include legal and financial advisory fees associated with acquisitions; and integration costs to convert to common policies, procedures, and information systems. Restructuring and other expenses include employee severance and other benefit-related costs, third-party consulting costs, facility-related costs, and other costs associated with the execution of our strategic restructuring plans; and transitional costs such as training, redundant salaries, and retention bonuses for certain critical personnel. Certain prior period amounts have been reclassified to conform to the current year presentation. Such reclassifications have no material effect on the Company's previously reported consolidated financial position, results of operations or cash flow. The Company has evaluated events that occurred during the period subsequent to the balance sheet date through the filing date of this Form 10-Q. Refer to Note 16 for more information.

EARNINGS PER SHARE

3 Months Ended

Mar. 31, 2013

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

Loss Per Share

The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):



	Three Months Ended March 31,
	2013			2012
Numerator:
Loss from continuing operations, net of income taxes	$	(7,470	)	$	(2,023	)
Loss from discontinued operations, net of income taxes	(658		)	(680		)
Net loss	$	(8,128	)	$	(2,703	)

Denominator - Basic:
Weighted average number of common shares outstanding	57,047			55,307

Basic loss from continuing operations	$	(0.13	)	$	(0.04	)
Basic loss from discontinued operations	(0.01		)	(0.01		)
Basic loss	$	(0.14	)	$	(0.05	)

Denominator - Diluted:
Weighted average number of common shares outstanding	57,047			55,307
Common share equivalents of outstanding stock options and restricted awards	—			—
Total diluted shares outstanding	57,047			55,307

Diluted loss from continuing operations	$	(0.13	)	$	(0.04	)
Diluted loss from discontinued operations	(0.01		)	(0.01		)
Diluted loss	$	(0.14	)	$	(0.05	)

ASC Topic 260, Earnings Per Share, requires that income from continuing operations be used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Thus, the computation of diluted shares for the three months ended March 31, 2013 and 2012 excludes the effect of 3.4 million warrants with an exercise price of $10 issued in connection with the acquisition of Critical Homecare Solutions Holdings, Inc. ("CHS") in 2010 as their inclusion would be anti-dilutive to earnings per common share from continuing operations. In addition to the warrants, the computation of diluted shares for the three months ended March 31, 2013 and 2012 excludes the effect of 6.5 million and 6.9 million, respectively, of other common stock equivalents as their inclusion would be anti-dilutive to earnings per common share from continuing operations.

RECENT ACCOUNTING PRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS	3 Months Ended
	Mar. 31, 2013
RECENT ACCOUNTING PRONOUNCEMENTS [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	In July 2012, the FASB issued ASU 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment (“ASU 2012-02”). ASU 2012-02 allows an entity to first assess qualitative factors to determine whether it is necessary to perform a quantitative impairment test. Under this amendment, an entity is not required to calculate the fair value of the indefinite-lived intangible asset unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The amendments include a number of events and circumstances for an entity to consider in conducting the qualitative assessment. The Company adopted ASU 2012-02 on January 1, 2013. The adoption of this statement did not have a material effect on the Company's Unaudited Consolidated Financial Statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=6958853&loc=d3e46468-122699

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22580-107794

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 01
-Paragraph b
-Subparagraph 6
-Article 10

+ Details

BUSINESS COMBINATIONS

3 Months Ended

Mar. 31, 2013

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

BUSINESS COMBINATIONS

HomeChoice Partners, Inc.

Description of the Transaction

On February 1, 2013, the Company acquired 100% of the ownership interest in HomeChoice Partners, Inc., a Delaware corporation ("HomeChoice") pursuant to that Stock Purchase Agreement dated December 12, 2012 (the "Purchase Agreement") by and among the Company, HomeChoice, DaVita HealthCare Partners Inc., a Delaware corporation and majority stockholder of HomeChoice, and the other stockholders of HomeChoice. The purchase price was $70 million, plus a $2.3 million purchase price adjustment based in part on the net working capital of HomeChoice at closing (the "Purchase Price"). The Purchase Price may also be increased in an amount up to $20 million if HomeChoice reaches certain performance milestones in the two years following the closing. The Company funded the acquisition with a combination of cash on hand and drawing on its revolving credit facility. HomeChoice is a provider of alternate-site infusion pharmacy services. Headquartered in Norfolk, VA, HomeChoice services approximately 15,000 patients annually and has fourteen infusion pharmacy locations in Pennsylvania, Washington, DC, Maryland, Virginia, North Carolina, South Carolina, Georgia, Missouri, and Alabama.

Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date. Due to the timing of this acquisition, these amounts are subject to change. The Company will finalize these amounts as it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in retrospective adjustments to the provisional amounts recognized at the acquisition date. These changes could be significant. The Company will finalize these amounts no later than a year from the acquisition date.

At March 31, 2013, there is a liability of $8.0 million recorded for the contingent increase in purchase price for HomeChoice. The fair value of the liability for contingent consideration was determined on the basis of the present value of various payout scenarios which were weighted on the basis of probability. Because the additional consideration may be earned over a two year period, $4.0 million is recorded in accrued expenses and other current liabilities and $4.0 million is recorded in other non-current liabilities.



	Amounts Recognized as of Acquisition Date (in thousands)
Accounts receivable	$	12,498
Inventories	1,984
Other current assets	154
Property and equipment	2,864
Identifiable intangible assets^(a)	4,000
Other non-current assets	30
Current liabilities	(4,624		)
Total identifiable net assets	16,906
Goodwill	63,419
Total fair value of cash and contingent consideration	$	80,325



(a)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:



	Weighted- Average Useful Lives	Amounts Recognized as of Acquisition Date (in thousands)
Customer relationships	5 mo. - 3 years	$	2,000
Trademarks	23 months	1,000
Non-compete agreements	1 year	1,000
Total identifiable intangible assets acquired		$	4,000

Impact of Acquisition on the Consolidated Financial Statements

The revenues of HomeChoice for the period from the acquisition date to March 31, 2013 were $10.8 million, and the loss from continuing operations was $0.8 million. The loss from continuing operations includes the effects of $0.8 million of acquisition-related costs, included in the acquisition and integration expenses line of the Unaudited Consolidated Statements of Operations.

InfuScience, Inc.

Description of the Transaction

On July 31, 2012, the Company acquired 100% of InfuScience, Inc. (“InfuScience”) for a cash payment of $38.3 million. The purchase price could increase to $41.4 million based on the results of operations during the 24 month period following the closing. InfuScience acquires, develops and operates businesses providing alternate site infusion pharmacy services. Through this acquisition, BioScrip has added five infusion centers located in Eagan, Minnesota; Omaha, Nebraska; Chantilly, Virginia; Charleston, South Carolina; and Savannah, Georgia.

Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date. These amounts are provisional and subject to change. The Company will finalize these amounts as it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in retrospective adjustments to the provisional amounts recognized at the acquisition date. These changes could be significant. The Company will finalize these amounts no later than a year from the acquisition date.

At March 31, 2013, there is a liability of $3.1 million recorded for the contingent increase in purchase price. The fair value of the liability for contingent consideration was determined on the present value and probability of payout. The liability is recorded in accrued expenses and other current liabilities.



	Amounts Recognized as of Acquisition Date (in thousands)
Cash	$	23
Accounts receivable	4,938
Inventories	586
Other current assets	371
Property and equipment	751
Identifiable intangible assets^(a)	400
Other non-current assets	349
Current liabilities	(4,428		)
Total identifiable net assets	2,990
Goodwill	38,429
Total fair value of cash and contingent consideration	$	41,419

______________________



(a)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:



	Weighted- Average Useful Lives (Months)	Amounts Recognized as of Acquisition Date (in thousands)
InfuScience customer relationships	5	400
Total identifiable intangible assets acquired	5	$	400

Impact of Acquisition on the Consolidated Financial Statements

The revenues of InfuScience for the three months ended March 31, 2013 were $11.4 million, and the loss from continuing operations was $1.0 million. The loss from continuing operations reflects the effects of $0.1 million of acquisition-related costs, included in the acquisition and integration expenses line of the Unaudited Consolidated Statements of Operations.

Pro Forma Impact of Business Combinations

The following table presents unaudited pro forma consolidated results of operations for the three-month periods ended March 31, 2013 and 2012, as if the HomeChoice and InfuScience acquisitions had occurred as of January 1, 2012 (in thousands except share data):



	Three Months Ended March 31,
	2013		2012
Revenues	205,163		182,458
Total net loss from continuing operations	(4,815	)	(3,917	)
Basic loss per share	(0.08	)	(0.07	)
Diluted loss per share	(0.08	)	(0.07	)

The unaudited pro forma consolidated results of operations were prepared using the acquisition method of accounting and are based on the historical financial information of the Company, HomeChoice and InfuScience. Except to the extent realized in the three-month period ended March 31, 2013, the unaudited pro forma information does not reflect any cost savings, operating synergies and other benefits that the Company may achieve as a result of these acquisitions, or the expenses to be incurred to achieve these savings, operating synergies and other benefits. In addition, except to the extent recognized in the three-month period ended March 31, 2013, the unaudited pro forma information does not reflect the costs to integrate the operations of the Company with HomeChoice and InfuScience.

The unaudited pro forma information is not necessarily indicative of what the Company's consolidated results of operations actually would have been had the HomeChoice and InfuScience acquisitions been completed on January 1, 2012. In addition, the unaudited pro forma information does not purport to project the future results of operations of the Company. The unaudited pro forma information primarily reflects the following adjustments related to the acquisition (in thousands):



	Three Months Ended March 31,
	2013			2012
Interest expense	$	292		$	1,063
Tax benefit	$	(117	)	$	(479	)
Amortization expense	$	(495	)	$	1,304

Expenses incurred to integrate acquisitions are recorded in the acquisition and integration expenses line of the Unaudited Consolidated Statements of Operations. These costs include legal and financial advisory fees associated with acquisitions; and integration costs to convert to common policies, procedures, and information systems.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1383-128463

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph F4
-Subparagraph e
-Appendix F

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

DISCONTINUED OPERATIONS

3 Months Ended

Mar. 31, 2013

DISCONTINUED OPERATIONS [Abstract]

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

DISCONTINUED OPERATIONS

On February 1, 2012, the Company entered into a Community Pharmacy and Mail Business Purchase Agreement (the “Asset Purchase Agreement”) by and among Walgreen Co. and certain subsidiaries (collectively, the "Buyers") and the Company and certain subsidiaries (collectively, the "Sellers") with respect to the sale of certain assets, rights and properties (the “Pharmacy Services Asset Sale”) relating to the Sellers' traditional and specialty pharmacy mail operations and community retail pharmacy stores.

Pursuant to the terms of the Asset Purchase Agreement, the Company received a total purchase price of approximately $173.8 million during 2012, including approximately $158.8 million at closing on May 4, 2012 (which included monies received for the inventories on hand attributable to the operations subject to the Pharmacy Services Asset Sale), and a subsequent purchase price payment of $15.0 million based on events related directly or indirectly to the Buyers' retention of certain business after the closing. Similarly, the Company may be required to refund up to approximately $6.4 million of cash received to the Buyers under certain circumstances, within the 14 months period following the closing. Any gain associated with this contingency will be recorded when the final amount retained or refunded is known. The $173.8 million purchase price excluded all accounts receivable and working capital liabilities relating to the operations subject to the Pharmacy Services Asset Sale, which were retained by the Company. Approximately $1.3 million of these net assets remained at March 31, 2013.

As a result of the Pharmacy Services Asset Sale, the Company recognized a pretax gain of $101.6 million, net of transaction costs and other one-time charges as a result of the transaction in the year ended December 31, 2012. As of March 31, 2013 and December 31, 2012, there were accruals of $43 thousand and $134 thousand, respectively, related to these costs in accrued expenses and other current liabilities and other non-current liabilities on the Unaudited Consolidated Balance Sheets. The accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits			Other Costs		Total
Liability balance as of December 31, 2012	$	45		$	89	$	134
Cash payments	(2		)	—		(2		)
Liability balance as of March 31, 2013	$	43		$	89	$	132

In addition, the Company and its subsidiaries and certain subsidiaries of the Buyers entered into an agreement concurrently with the Asset Purchase Agreement which provided that the Company ceased to be the sole fulfillment pharmacy for customers who came through the drugstore.com website. The agreement provided for a cash payment of $3.0 million to the Company and the payment of $2.9 million to the Buyers related to contingent consideration from the Company's 2010 acquisition of the prescription pharmacy business of DS Pharmacy, both of which occurred during the three months ended March 31, 2012.

The transaction included the sale of 27 community pharmacy locations, and certain assets of three community pharmacy locations, and three traditional and specialty mail service operations, which constituted all of the Company's operations in the community pharmacy and mail order lines of business. Two mail order locations that were not transferred as part of the Pharmacy Services Asset Sale were redeployed to provide infusion pharmacy services. On May 4, 2012, the carrying value of the assets included in the Pharmacy Services Asset Sale were as follows (in thousands):



Inventory	$	30,560
Prepaid expenses and other current assets	299
Total current assets	30,859
Property and equipment, net	1,592
Goodwill	11,754
Intangible assets, net	2,503
Total assets	$	46,708

The operating results of the traditional and specialty pharmacy mail operations and community pharmacies for the three months ended March 31, 2013 and 2012, are summarized below. These results include costs directly attributable to the components of the businesses which were divested. Interest expense was immaterial and $0.7 million for the three months ended March 31, 2013 and 2012, respectively, and has been allocated to discontinued operations on the basis of the borrowing base that was reduced as a result of the Pharmacy Services Asset Sale and the working capital associated with the business that was disposed. An immaterial amount of income tax expense was allocated to discontinued operations for the three months ended March 31, 2013 and 2012. Depreciation expense was no longer incurred on fixed assets included in the disposal group as of February 1, 2012, the date the Company entered into the Asset Purchase Agreement.



Discontinued Operations Results
(in thousands)

	Three Months Ended March 31,
	2013			2012

Revenue	$	(20	)	$	338,103

Gross profit	$	(68	)	$	22,960

Operating expense	$	619		$	22,916

Loss from discontinued operations, net of income taxes	$	(658	)	$	(680	)

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 43-48
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

GOODWILL AND INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

GOODWILL AND INTANGIBLE ASSETS

Goodwill consisted of the following as of March 31, 2013 and December 31, 2012 (in thousands):



	March 31, 2013		December 31, 2012
Infusion	$	367,706	$	304,282
Home Health Services	33,784		33,784
PBM Services	12,744		12,744
Total	$	414,234	$	350,810

Intangible assets consisted of the following as of March 31, 2013 and December 31, 2012 (in thousands):



		March 31, 2013
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Indefinite Lived Assets
Certificates of need	indefinite	$	9,600	$	—		$	9,600
Nursing trademarks	indefinite	5,800		—			5,800
		15,400		—			15,400
Definite Lived Assets
Infusion customer relationships	5 months - 3 years	11,300		(9,083		)	2,217
Infusion trademarks	23 months - 3 years	3,600		(2,687		)	913
Non-compete agreements	1 year	1,000		(166		)	834
		15,900		(11,936		)	3,964
		$	31,300	$	(11,936	)	$	19,364



		December 31, 2012
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Indefinite Lived Assets
Certificates of need	indefinite	$	9,600	$	—		$	9,600
Nursing trademarks	indefinite	5,800		—			5,800
		15,400		—			15,400
Definite Lived Assets
Infusion customer relationships	6 months- 3 years	9,300		(7,447		)	1,853
Infusion trademarks	3 years	2,600		(2,407		)	193
		11,900		(9,854		)	2,046
		$	27,300	$	(9,854	)	$	17,446

The estimated fair value of intangible assets was calculated using level 3 inputs based upon the present value of anticipated future benefits. Total amortization of intangible assets was $2.1 million and $0.9 million for the three months ended March 31, 2013 and 2012, respectively. Amortization expense is expected to be the following (in thousands):



2013 (nine months)	$	2,664
2014	939
2015 and beyond	361
Total	$	3,964

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

RESTRUCTURING AND OTHER EXPENSES

3 Months Ended

Mar. 31, 2013

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

RESTRUCTURING AND OTHER EXPENSES

Restructuring and other expenses included expenses resulting from the execution of our strategic assessment and related restructuring plans, consisting primarily of employee severance and other benefit-related costs, third-party consulting costs, facility-related costs, and certain other costs. It also included other transitional costs such as training, redundant salaries, and retention bonuses for certain critical personnel.

In the fourth quarter of 2010, the Company commenced a strategic assessment of its business and operations ("Restructuring Phase I"). This assessment focused on expanding revenue opportunities and lowering corporate overhead, including workforce and benefit reductions and facility rationalization. In addition to addressing corporate overhead, the strategic assessment examined the Company's market strengths and opportunities and compared the Company's position to that of its competitors. As a result of the assessment, the Company focused its growth on investments in the Infusion and Home Health Services segments and elected to pursue offers for its traditional and specialty pharmacy mail operations and community pharmacy stores. Accordingly, the Company consummated the Pharmacy Services Asset Sale relating to its traditional and specialty pharmacy mail operations and community retail pharmacy stores. During the three months ended June 30, 2012, as a result of the divestiture process, the Company's management team commenced an assessment of the Company's continuing operations in order to align its corporate structure with its remaining operations ("Restructuring Phase II").

The Company anticipates that additional restructuring will occur and thus significant additional charges such as the write down of certain long−lived assets, employee severance, other restructuring type charges, temporary redundant expenses, potential cash bonus payments and potential accelerated payments or termination costs for certain of its contractual obligations, could impact the Company's future Consolidated Financial Statements.

Restructuring Phase I

As a result of Restructuring Phase I, the Company incurred restructuring expenses of approximately $0.3 million during the three months ended March 31, 2012. The Company did not incur restructuring expense related to Phase I during the three months ended March 31, 2013, though some amounts previously accrued were adjusted. Restructuring expenses during the three months ended March 31, 2012 consisted of approximately $0.3 million of third-party consulting costs.

Since inception of Restructuring Phase I, the Company has incurred approximately $10.0 million in total Phase I expenses, consisting of $4.4 million of third-party consulting costs, $4.2 million of employee severance and other benefit-related costs related to workforce reductions, and $1.4 million of facility-related costs.

The restructuring costs are included in restructuring and other expenses on the Unaudited Consolidated Statements of Operations and as part of the calculation of Segment Adjusted EBITDA, as defined in Note 11. As of March 31, 2013, there are restructuring accruals of $0.9 million related to Phase I included in accrued expenses and other current liabilities and other non-current liabilities on the Unaudited Consolidated Balance Sheets. The restructuring accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits		Consulting Costs			Facility-Related Costs			Total
Liability balance as of December 31, 2012	$	163	$	20		$	841		$	1,024
Expenses	—		(20		)	(98		)	(118		)
Cash payments	—		—			(31		)	(31		)
Liability balance as of March 31, 2013	$	163	$	—		$	712		$	875

Restructuring Phase II

As a result of Restructuring Phase II, the Company incurred restructuring expenses of approximately $0.5 million during the three months ended March 31, 2013. The Company did not incur restructuring expense related to Phase II during the three months ended March 31, 2012. Restructuring expenses for the three months ended March 31, 2013 included approximately $0.4 million of employee severance and other benefit-related costs related to workforce reductions and $0.1 million in other costs.

Since inception of Phase II of restructuring, the Company has incurred approximately $2.4 million in total expenses, consisting of $1.5 million of employee severance and other benefit-related costs related to workforce reductions, $0.3 million in third party consulting costs and $0.6 million of other costs.

The restructuring costs are included in restructuring and other expenses on the Unaudited Consolidated Statements of Operations and as part of the calculation of Segment Adjusted EBITDA, as defined in Note 11. As of March 31, 2013, there are restructuring accruals of $0.7 million related to Phase II included in accrued expenses and other current liabilities and other non-current liabilities on the Unaudited Consolidated Balance Sheets. The restructuring accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits			Consulting Costs			Other Costs			Total
Liability balance as of December 31, 2012	$	559		$	145		$	—		$	704
Expenses	382			19			73			474
Cash payments	(296		)	(145		)	(73		)	(514		)
Liability balance as of March 31, 2013	$	645		$	19		$	—		$	664

Other transitional costs totaled $0.9 million and $0.1 million for the three months ended March 31, 2013 and March 31, 2012, respectively.

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References + Details

PROPERTY AND EQUIPMENT

3 Months Ended

Mar. 31, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

PROPERTY AND EQUIPMENT

Property and equipment consisted of the following (in thousands):



	March 31, 2013			December 31, 2012
Computer and office equipment, including equipment acquired under capital leases	$	14,976		$	14,443
Software capitalized for internal use	9,939			9,939
Vehicles, including equipment acquired under capital leases	1,630			1,540
Medical equipment	17,627			16,466
Work in progress	7,178			4,315
Furniture and fixtures	3,539			3,219
Leasehold improvements	8,383			7,164
	63,272			57,086
Less: Accumulated depreciation	(35,505		)	(33,365		)
Property and equipment, net	$	27,767		$	23,721

The Company had an insignificant amount of vehicles under capital lease as of March 31, 2013 and December 31, 2012.

Depreciation Expense

Depreciation expense, including expense related to assets under capital lease, for the three months ended March 31, 2013 and 2012, was $2.5 million and $1.9 million, respectively. Depreciation expense for the three months ended March 31, 2013 and 2012, included $0.4 million and $0.7 million, respectively, for costs related to software capitalized for internal use.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

DEBT

3 Months Ended

Mar. 31, 2013

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

DEBT

As of March 31, 2013 the Company’s long-term debt consisted of the following obligations (in thousands):



Revolving credit facility	$	27,053
Senior unsecured notes	225,000
Capital leases	1,311
	253,364
Less - obligations maturing within one year	27,992
Long term debt - net of current portion	$	225,372

On July 3, 2012, the Company entered into a Third Amendment to the Second Amended and Restated Credit Agreement, by and among the Company, as borrower, all of its subsidiaries as guarantors thereto, the lenders, Healthcare Finance Group, LLC, an administrative agent, and the other parties thereto. The amendment reduced revolving commitments from $150 million to $125 million; eliminated the minimum revolving balance requirement; increased the basket limitation for loans and advances to third parties and investments in permitted joint ventures to $60 million; removed the dollar limitation on permitted acquisitions so long as the proposed acquisition meets the pro forma and other conditions; lowered the LIBOR floor to 1.00% from 1.25%; and modified the definition of the term “Consolidated EBITDA”. As of March 31, 2013, borrowings under the senior secured revolving credit facility totaled $27.1 million.

As of March 31, 2013, the carrying amount of the Company's senior unsecured notes was $225.0 million, and the estimate of the fair value of the senior unsecured notes, based on current market rates for debt of the same risk and maturities, was $246.4 million. The estimated fair value was calculated using level 3 inputs and was based on current market rates for debt of the same risk and maturities.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Legal Proceedings

On June 30, 2009, Professional Home Care Services, Inc., or PHCS, one of the subsidiaries the Company acquired through its acquisition of CHS, was sued by Alexander Infusion, LLC, a New York-based home infusion company, in the Supreme Court of the State of New York. The complaint alleges principally breach of contract arising in connection with PHCS's failure to consummate an acquisition of Alexander Infusion after failing to satisfy the conditions to PHCS's obligation to close. Alexander Infusion has sued for $3.5 million in damages. The Company believes Alexander Infusion's claims to be without merit and intends to continue to defend against the allegations vigorously. Furthermore, under the merger agreement, subject to certain limits, the former CHS stockholders agreed to indemnify the Company in connection with any losses arising from claims made in respect of the acquisition agreement entered into between PHCS and Alexander Infusion.

Government Regulation

Various Federal and state laws and regulations affecting the healthcare industry do or may impact the Company's current and planned operations, including, without limitation, Federal and state laws prohibiting kickbacks in government health programs, Federal and state antitrust and drug distribution laws, and a wide variety of consumer protection, insurance and other state laws and regulations. Management strives to maintain the Company in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are subject to rapid change and often are uncertain in their application. As controversies continue to arise in the healthcare industry (for example, the efforts of Plan Sponsors and pharmacy benefit managers to limit formularies, alter drug choice and establish limited networks of participating pharmacies), Federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted.

From time to time, the Company responds to subpoenas and requests for information from governmental agencies. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance will all laws, rules and regulations that affect its business and operations, there can be no assurance that the Company will not be subject to scrutiny or challenge under one or more existing laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company's Consolidated Financial Statements. A violation of the Federal anti-kickback statute, for example, may result in substantial criminal penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant. Further, there can be no assurance the Company will be able to maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company's Unaudited Consolidated Financial Statements.

Legal Settlements

In May 2011, the Company was advised of a qui tam lawsuit filed under seal in federal court in Minnesota in 2006 and naming the Company as defendant. The complaint alleged violations of healthcare statutes and regulations by the Company and predecessor companies dating back to 2000. During the year ended December 31, 2012, the Company entered into a final settlement under which the Company paid the states $0.6 million and the federal government $4.4 million resolving all issues alleged in the complaint and the government's investigation in exchange for a release and dismissal of the claims. A related qui tam relator's employment termination claim and her lawyer's statutory legal fee claim were also resolved. During the year ended December 31, 2012, the Company recorded a legal settlement expense of $0.8 million related to the settlement. No related expenses were included in net income during the three months ended March 31, 2013 or 2012 in the accompanying Unaudited Consolidated Statements of Operations. As of March 31, 2013 there was no remaining liability.

The Company has accrued a liability of $2.3 million for a probable settlement related to merger and acquisition activities. The amount is included in the acquisition and integration expense line on the Unaudited Consolidated Statements of Operations and in accrued expenses and other current liabilities on the Unaudited Consolidated Balance Sheet as of March 31, 2013. The liability is likely to be paid in the second quarter of 2013.

Leases

The Company leases its facilities and certain equipment under various operating leases with third parties. The majority of these leases contain escalation clauses that increase base rent payments based upon either the Consumer Price Index or an agreed upon schedule.

In addition, the Company utilizes capital leases agreements with third parties to obtain certain assets such as vehicles. Interest rates on capital leases are both fixed and variable and range from 3% to7%.

As of March 31, 2013, future minimum lease payments, including interest, under operating and capital leases are as follows (in thousands):



	Operating Leases		Capital Leases		Total
2013 (nine months)	$	5,436	$	185	$	5,621
2014	6,535		225		6,760
2015	5,481		192		5,673
2016	4,518		23		4,541
2017	3,815		—		3,815
2018 and thereafter	5,024		—		5,024
Total	$	30,809	$	625	$	31,434

Rent expense for leased facilities and equipment was approximately $1.8 million and $1.5 million for the three months ended March 31, 2013 and 2012, respectively.

Purchase Commitments

As of March 31, 2013, the Company had commitments to purchase prescription drugs from drug manufacturers of approximately $27.7 million during the remainder of 2013. These purchase commitments are made at levels expected to be used in the normal course of business.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

OPERATING AND REPORTABLE SEGMENTS

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

The Company's operating and reportable segments, “Infusion Services," "Home Health Services” and “PBM Services,” reflect how the Company's chief operating decision maker reviews the Company's results in terms of allocating resources and assessing performance.

The Infusion Services operating and reportable segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Infusion services include the dispensing and administering of infusion-based drugs, which typically require additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes. Home infusion services also include the dispensing of self-injectable therapies.

The Home Health Services operating and reportable segment provides services including the provision of skilled nursing services and therapy visits, private duty nursing services, hospice services, rehabilitation services and medical social services to patients primarily in their home.

The PBM Services operating and reportable segment consists of integrated pharmacy benefit management ("PBM") services, which primarily consists of discount card programs. The discount card programs provide a cost effective alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. Under these discount programs, individuals who present a discount card at any of the Company's participating network pharmacies receive prescription medications at a discounted price compared to the retail price.

The Company's chief operating decision maker evaluates segment performance and allocates resources based on Segment Adjusted EBITDA. Segment Adjusted EBITDA is defined as income (loss) from continuing operations, net of income taxes adjusted for net interest expense, income tax expense (benefit), depreciation, amortization of intangibles and stock-based compensation expense and prior to the allocation of certain corporate expenses. Segment Adjusted EBITDA excludes acquisition, integration, and transitional expenses; restructuring expense; and other expenses related to the Company's strategic assessment. Segment Adjusted EBITDA is a measure of earnings that management monitors as an important indicator of operating and financial performance. The accounting policies of the operating and reportable segments are consistent with those described in the Company's summary of significant accounting policies.

Segment Reporting Information

(in thousands)



	Three Months Ended March 31,
	2013			2012
Results of Operations:
Revenue:
Infusion Services - product revenue	$	150,024		$	106,803
Infusion Services - service revenue	4,353			2,250
Total Infusion Services revenue	154,377			109,053

Home Health Services - service revenue	17,942			16,711

PBM Services - service revenue	26,752			29,869

Total revenue	$	199,071		$	155,633

Adjusted EBITDA by Segment before corporate overhead:
Infusion Services	$	12,315		$	7,783
Home Health Services	883			1,080
PBM Services	6,199			6,098
Total Segment Adjusted EBITDA	19,397			14,961

Corporate overhead	(7,916		)	(6,582		)

Interest expense, net	(6,478		)	(6,569		)
Income tax benefit	(58		)	502
Depreciation	(2,459		)	(1,931		)
Amortization of intangibles	(2,082		)	(879		)
Stock-based compensation expense	(1,973		)	(966		)
Acquisition and integration expenses	(4,623		)	(172		)
Restructuring and other expenses	(1,278		)	(387		)
Loss from continuing operations, net of income taxes	$	(7,470	)	$	(2,023	)

Supplemental Operating Data
	March 31, 2013			December 31, 2012
Total Assets:
Infusion Services	$	523,857		$	438,623
Home Health Services	63,280			62,403
PBM Services	30,909			36,354
Corporate unallocated, including cash and cash equivalents	45,189			95,813
Assets associated with discontinued operations, not sold	2,479			9,183
Total	$	665,714		$	642,376

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

CONCENTRATION OF RISK	3 Months Ended
CONCENTRATION OF RISK	Mar. 31, 2013
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	CONCENTRATION OF RISK Customer and Credit Risk The Company provides trade credit to its customers in the normal course of business. One payor accounted for approximately 21% and 16% of revenue during the three months ended March 31, 2013 and 2012, respectively. The majority of the revenue is related to the Infusion Services segment. Therapy Revenue Risk The Company sells products related to the Immune Globulin therapy, which represented 17% and 21% of revenue during the three months ended March 31, 2013 and 2012, respectively. The revenue is related to the Infusion Services segment.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6442-108592

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 21, 22, 24
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

INCOME TAXES

3 Months Ended

Mar. 31, 2013

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

INCOME TAXES

The Company’s Federal and state income tax expense (benefit) from continuing operations is summarized in the following table (in thousands):



	Three Months Ended March 31,
	2013			2012
Current
Federal	$	(519	)	$	(29	)
State	120			(173		)
Total Current	(399		)	(202		)
Deferred
Federal	399			(262		)
State	58			(38		)
Total deferred	457			(300		)
Total income tax expense (benefit)	$	58		$	(502	)

The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate is as follows for the three months ended March 31, 2013 and 2012 (in thousands):



	Three Months Ended March 31,
	2013			2012
Tax benefit at statutory rate	$	(2,594	)	$	(884	)
State tax benefit, net of Federal taxes	(47		)	(103		)
Change in tax contingencies	(512		)	6
Valuation allowance changes affecting income tax expense	2,818			430
Transaction related costs	236			—
Officers compensation and other	157			49
Income tax expense (benefit)	$	58		$	(502	)

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

STOCK-BASED COMPENSATION	3 Months Ended
STOCK-BASED COMPENSATION	Mar. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	STOCK-BASED COMPENSATION BioScrip Equity Incentive Plans Under the Company's Amended and Restated 2008 Equity Incentive Plan (as amended and restated, the “2008 Plan”), the Company may issue, among other things, incentive stock options (“ISOs”), non-qualified stock options (“NQSOs”), stock appreciation rights ("SARs"), restricted stock, performance shares and performance units to employees and directors. While SARS are authorized under the 2008 Plan, they may also be issued outside of the plan. Under the 2008 Plan, 3,580,000 shares were originally reserved for issuance (subject to adjustment for grants made under the Company's 2001 Incentive Stock Plan (the “2001 Plan”) after January 1, 2008, as well as for forfeitures, expirations or awards that under the 2001 Plan otherwise settled in cash after the adoption thereof). Upon the effective date of the 2008 Plan, the Company ceased making grants under the 2001 Plan. The 2008 Plan is administered by the Company's Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors. On June 10, 2010, the Company's stockholders approved an amendment to the 2008 Plan to increase the number of authorized shares of common stock available for issuance by 3,275,000 shares to 6,855,000 shares. As of March 31, 2013, there were 802,960 shares that remained available for grant under the 2008 Plan. BioScrip/CHS Equity Plan Effective upon closing of the acquisition of CHS, the CHS 2006 Equity Incentive Plan was adopted by the Company and renamed the “BioScrip/CHS 2006 Equity Incentive Plan” (as amended and restated, the “BioScrip/CHS Plan”). There were 13,000,000 shares of CHS common stock originally authorized for issuance under the CHS 2006 Equity Incentive Plan, which were converted into 3,106,315 shares of BioScrip common stock, and adjusted using the exchange ratio defined by the merger agreement. The Board of Directors further amended the BioScrip/CHS Plan to provide for it to have substantially the same terms and provisions as the 2008 Plan. Of the options authorized and outstanding under the BioScrip/CHS Plan on the date of the acquisition, 716,086 options were designated as “rollover” options. These rollover options were issued to the top five executives of CHS at the time of the acquisition, and otherwise remain subject to the term of the BioScrip/CHS Plan, as amended, and fully vested on the date of conversion. Under the terms of the BioScrip/CHS Plan, any shares of BioScrip common stock subject to rollover options that expire or otherwise terminate before all or any part of the shares subject to such options have been purchased as a result of the exercise of such options shall remain available for issuance under the BioScrip/CHS Plan. The remaining 2,390,229 shares are authorized for issuance under the BioScrip/CHS Plan. These shares may be used for awards under the BioScrip/CHS Plan, provided that awards using such available shares are not made after the date that awards or grants could have been made under the terms of the pre-existing plan, and are only made to individuals who were not employees or directors of BioScrip or an affiliate or subsidiary of BioScrip prior to such acquisition. As of March 31, 2013, there were 1,054,528 shares that remained available under the BioScrip/CHS Plan. Stock Options The Company recognized compensation expense related to stock options of $1.4 million and $0.7 million during the three months ended March 31, 2013 and 2012, respectively. Restricted Stock The Company recognized compensation expense related to restricted stock awards of $0.2 million and $0.1 million during the three months ended March 31, 2013 and 2012, respectively. Stock Appreciation Rights The Company recognized compensation expense related to stock appreciation rights awards of $0.4 million and $0.2 million during the three months ended March 31, 2013 and 2012, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SHELF REGISTRATION STATEMENT (Notes)	3 Months Ended
SHELF REGISTRATION STATEMENT (Notes)	Mar. 31, 2013
SHELF REGISTRATION STATEMENT [Abstract]
SHELF REGISTRATION STATMENT [Text Block]	The Company filed a shelf registration statement on Form S-3 on March 18, 2013 and related amendment subsequent to quarter end (see note 16, Subsequent Events) on April 2, 2013. Under the shelf registration statement, the Company, had the ability, immediately following effectiveness and prior to any offering thereunder, to raise up to $200 million, in one or more transactions, by selling common stock, preferred stock, debt securities, warrants and units. In addition, selling stockholders to be named in a prospectus supplement could sell immediately following effectiveness and prior to any offering thereunder, up to an aggregate of 12,682,831 shares of the Company's common stock, and up to an aggregate of 3,400,945 shares of the Company's common stock issuable upon the exercise of the Company's outstanding warrants. The registration statement was declared effective on April 4, 2013. Subsequent to quarter end the Company completed an underwritten public offering pursuant to this shelf registration (see note 16).

SUBSEQUENT EVENTS (Notes)	3 Months Ended
SUBSEQUENT EVENTS (Notes)	Mar. 31, 2013
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Stock Offering Pursuant to the shelf registration statement on Form S-3 declared effective on April 4, 2013 (see Note 15), the Company filed a prospectus supplement on April 22, 2013, in conjunction with an Underwriting Agreement relating to a public offering of 12,500,000 shares of the Company's common stock, including 3,125,000 shares of the Company's common stock offered by certain selling stockholders, at a price to the public of $12.00 per share (the "Offering Price") less underwriting discounts and commissions and other offering expenses payable by the Company and such selling stockholders. Under the terms of the Underwriting Agreement, the underwriters fully exercised their option to purchase an additional 1,875,000 shares of common stock at the Offering Price less underwriting discounts and commissions and other offering expenses payable by the Company and such selling stockholders. On April 24, 2013, the Company completed the offering and received $118.6 million in net proceeds from the offering. The Company did not receive any proceeds from the sale of shares by the selling stockholders. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include, among other things, financing growth, both organically and through acquisitions, investments, capital expenditures, repurchases of outstanding debt or equity securities, debt servicing requirements or redemption of our short-term or long-term borrowings, or for other working capital requirements. Refinancing of Existing Indebtedness On April 16, 2013, the Company announced its intention to partially refinance its existing indebtedness with the proceeds of a new senior secured credit facility, including a revolving credit facility and a term loan, in an approximate aggregate principal amount of $325 million. The Company entered into a best efforts commitment with respect to such credit facility to be arranged and syndicated by SunTrust Robinson Humphrey, Inc., Jefferies Finance LLC and Morgan Stanley Senior Credit Funding, Inc. The Company expects to use the proceeds of such credit facility to refinance its existing asset-based revolving credit facility, to redeem its outstanding 10.25% senior unsecured notes, and to support the working capital and general corporate needs of the Company. Disposal of Investment in Variable Interest Entity On April 19, 2013, the Company, along with all other minority investors, closed on the sale of its affiliate equity investment in a variable interest entity (see Note 1). At closing the Company received a cash payment of $8.5 million, with an additional $1.1 million held in escrow pending any working capital adjustments that may be necessary. Additionally, the Company will receive up to an additional $3.0 million in services or cash during the two years following close. The sale of this equity interest will not have a material effect on the financial statements. Employee Stock Purchase Plan On April 2, 2013, the Company filed a Registration Statement on Form S-8 to register 750,000 shares of Common Stock, par value $0.0001 per share, for issuance under the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP was approved at the Company's 2013 Annual Meeting of Stockholders.

EARNINGS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2013

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):



	Three Months Ended March 31,
	2013			2012
Numerator:
Loss from continuing operations, net of income taxes	$	(7,470	)	$	(2,023	)
Loss from discontinued operations, net of income taxes	(658		)	(680		)
Net loss	$	(8,128	)	$	(2,703	)

Denominator - Basic:
Weighted average number of common shares outstanding	57,047			55,307

Basic loss from continuing operations	$	(0.13	)	$	(0.04	)
Basic loss from discontinued operations	(0.01		)	(0.01		)
Basic loss	$	(0.14	)	$	(0.05	)

Denominator - Diluted:
Weighted average number of common shares outstanding	57,047			55,307
Common share equivalents of outstanding stock options and restricted awards	—			—
Total diluted shares outstanding	57,047			55,307

Diluted loss from continuing operations	$	(0.13	)	$	(0.04	)
Diluted loss from discontinued operations	(0.01		)	(0.01		)
Diluted loss	$	(0.14	)	$	(0.05	)

BUSINESS COMBINATIONS (Tables)

3 Months Ended

Mar. 31, 2013

Business Acquisition [Line Items]

Business Acquisition, Pro Forma Information [Table Text Block]



	Three Months Ended March 31,
	2013		2012
Revenues	205,163		182,458
Total net loss from continuing operations	(4,815	)	(3,917	)
Basic loss per share	(0.08	)	(0.07	)
Diluted loss per share	(0.08	)	(0.07	)

Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table Text Block]

The unaudited pro forma information primarily reflects the following adjustments related to the acquisition (in thousands):



	Three Months Ended March 31,
	2013			2012
Interest expense	$	292		$	1,063
Tax benefit	$	(117	)	$	(479	)
Amortization expense	$	(495	)	$	1,304

HomeChoice Partners, Inc. [Member]

Business Acquisition [Line Items]

Schedule of Purchase Price Allocation [Table Text Block]



	Amounts Recognized as of Acquisition Date (in thousands)
Accounts receivable	$	12,498
Inventories	1,984
Other current assets	154
Property and equipment	2,864
Identifiable intangible assets^(a)	4,000
Other non-current assets	30
Current liabilities	(4,624		)
Total identifiable net assets	16,906
Goodwill	63,419
Total fair value of cash and contingent consideration	$	80,325



(a)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]



	Weighted- Average Useful Lives	Amounts Recognized as of Acquisition Date (in thousands)
Customer relationships	5 mo. - 3 years	$	2,000
Trademarks	23 months	1,000
Non-compete agreements	1 year	1,000
Total identifiable intangible assets acquired		$	4,000

InfuScience, Inc. [Member]

Business Acquisition [Line Items]

Schedule of Purchase Price Allocation [Table Text Block]



	Amounts Recognized as of Acquisition Date (in thousands)
Cash	$	23
Accounts receivable	4,938
Inventories	586
Other current assets	371
Property and equipment	751
Identifiable intangible assets^(a)	400
Other non-current assets	349
Current liabilities	(4,428		)
Total identifiable net assets	2,990
Goodwill	38,429
Total fair value of cash and contingent consideration	$	41,419

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]



	Weighted- Average Useful Lives (Months)	Amounts Recognized as of Acquisition Date (in thousands)
InfuScience customer relationships	5	400
Total identifiable intangible assets acquired	5	$	400

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References + Details

DISCONTINUED OPERATIONS (Tables)

3 Months Ended

Mar. 31, 2013

DISCONTINUED OPERATIONS [Abstract]

Schedule of Disposal Groups, Including Discontinued Operations, Balance Sheet [Table Text Block]

, the carrying value of the assets included in the Pharmacy Services Asset Sale were as follows (in thousands):



Inventory	$	30,560
Prepaid expenses and other current assets	299
Total current assets	30,859
Property and equipment, net	1,592
Goodwill	11,754
Intangible assets, net	2,503
Total assets	$	46,708

charges associated with exit or disposal activity [Table Text Block]

The accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits			Other Costs		Total
Liability balance as of December 31, 2012	$	45		$	89	$	134
Cash payments	(2		)	—		(2		)
Liability balance as of March 31, 2013	$	43		$	89	$	132

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]



Discontinued Operations Results
(in thousands)

	Three Months Ended March 31,
	2013			2012

Revenue	$	(20	)	$	338,103

Gross profit	$	(68	)	$	22,960

Operating expense	$	619		$	22,916

Loss from discontinued operations, net of income taxes	$	(658	)	$	(680	)

- Definition

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

+ References + Details

GOODWILL AND INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Amortization expense is expected to be the following (in thousands):



2013 (nine months)	$	2,664
2014	939
2015 and beyond	361
Total	$	3,964

Schedule of Goodwill [Table Text Block]

Goodwill consisted of the following as of March 31, 2013 and December 31, 2012 (in thousands):



	March 31, 2013		December 31, 2012
Infusion	$	367,706	$	304,282
Home Health Services	33,784		33,784
PBM Services	12,744		12,744
Total	$	414,234	$	350,810

Schedule of Intangible Assets by Major Class [Table Text Block]

Intangible assets consisted of the following as of March 31, 2013 and December 31, 2012 (in thousands):



		March 31, 2013
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Indefinite Lived Assets
Certificates of need	indefinite	$	9,600	$	—		$	9,600
Nursing trademarks	indefinite	5,800		—			5,800
		15,400		—			15,400
Definite Lived Assets
Infusion customer relationships	5 months - 3 years	11,300		(9,083		)	2,217
Infusion trademarks	23 months - 3 years	3,600		(2,687		)	913
Non-compete agreements	1 year	1,000		(166		)	834
		15,900		(11,936		)	3,964
		$	31,300	$	(11,936	)	$	19,364



		December 31, 2012
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Indefinite Lived Assets
Certificates of need	indefinite	$	9,600	$	—		$	9,600
Nursing trademarks	indefinite	5,800		—			5,800
		15,400		—			15,400
Definite Lived Assets
Infusion customer relationships	6 months- 3 years	9,300		(7,447		)	1,853
Infusion trademarks	3 years	2,600		(2,407		)	193
		11,900		(9,854		)	2,046
		$	27,300	$	(9,854	)	$	17,446

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References + Details

RESTRUCTURING AND OTHER EXPENSES (Tables)

3 Months Ended

Mar. 31, 2013

Phase I [Member]

Restructuring Cost and Reserve [Line Items]

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The restructuring accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits		Consulting Costs			Facility-Related Costs			Total
Liability balance as of December 31, 2012	$	163	$	20		$	841		$	1,024
Expenses	—		(20		)	(98		)	(118		)
Cash payments	—		—			(31		)	(31		)
Liability balance as of March 31, 2013	$	163	$	—		$	712		$	875

Phase II [Member]

Restructuring Cost and Reserve [Line Items]

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The restructuring accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits			Consulting Costs			Other Costs			Total
Liability balance as of December 31, 2012	$	559		$	145		$	—		$	704
Expenses	382			19			73			474
Cash payments	(296		)	(145		)	(73		)	(514		)
Liability balance as of March 31, 2013	$	645		$	19		$	—		$	664

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consisted of the following (in thousands):



	March 31, 2013			December 31, 2012
Computer and office equipment, including equipment acquired under capital leases	$	14,976		$	14,443
Software capitalized for internal use	9,939			9,939
Vehicles, including equipment acquired under capital leases	1,630			1,540
Medical equipment	17,627			16,466
Work in progress	7,178			4,315
Furniture and fixtures	3,539			3,219
Leasehold improvements	8,383			7,164
	63,272			57,086
Less: Accumulated depreciation	(35,505		)	(33,365		)
Property and equipment, net	$	27,767		$	23,721

DEBT (Tables)

3 Months Ended

Mar. 31, 2013

Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

As of March 31, 2013 the Company’s long-term debt consisted of the following obligations (in thousands):



Revolving credit facility	$	27,053
Senior unsecured notes	225,000
Capital leases	1,311
	253,364
Less - obligations maturing within one year	27,992
Long term debt - net of current portion	$	225,372

COMMITMENTS AND CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum lease payments for operating and capital leases [Table Text Block]

As of March 31, 2013, future minimum lease payments, including interest, under operating and capital leases are as follows (in thousands):



	Operating Leases		Capital Leases		Total
2013 (nine months)	$	5,436	$	185	$	5,621
2014	6,535		225		6,760
2015	5,481		192		5,673
2016	4,518		23		4,541
2017	3,815		—		3,815
2018 and thereafter	5,024		—		5,024
Total	$	30,809	$	625	$	31,434

OPERATING AND REPORTABLE SEGMENTS (Tables)

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Segment Reporting Information

(in thousands)



	Three Months Ended March 31,
	2013			2012
Results of Operations:
Revenue:
Infusion Services - product revenue	$	150,024		$	106,803
Infusion Services - service revenue	4,353			2,250
Total Infusion Services revenue	154,377			109,053

Home Health Services - service revenue	17,942			16,711

PBM Services - service revenue	26,752			29,869

Total revenue	$	199,071		$	155,633

Adjusted EBITDA by Segment before corporate overhead:
Infusion Services	$	12,315		$	7,783
Home Health Services	883			1,080
PBM Services	6,199			6,098
Total Segment Adjusted EBITDA	19,397			14,961

Corporate overhead	(7,916		)	(6,582		)

Interest expense, net	(6,478		)	(6,569		)
Income tax benefit	(58		)	502
Depreciation	(2,459		)	(1,931		)
Amortization of intangibles	(2,082		)	(879		)
Stock-based compensation expense	(1,973		)	(966		)
Acquisition and integration expenses	(4,623		)	(172		)
Restructuring and other expenses	(1,278		)	(387		)
Loss from continuing operations, net of income taxes	$	(7,470	)	$	(2,023	)

Supplemental Operating Data
	March 31, 2013			December 31, 2012
Total Assets:
Infusion Services	$	523,857		$	438,623
Home Health Services	63,280			62,403
PBM Services	30,909			36,354
Corporate unallocated, including cash and cash equivalents	45,189			95,813
Assets associated with discontinued operations, not sold	2,479			9,183
Total	$	665,714		$	642,376

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details

INCOME TAXES (Tables)

3 Months Ended

Mar. 31, 2013

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

INCOME TAXES

The Company’s Federal and state income tax expense (benefit) from continuing operations is summarized in the following table (in thousands):



	Three Months Ended March 31,
	2013			2012
Current
Federal	$	(519	)	$	(29	)
State	120			(173		)
Total Current	(399		)	(202		)
Deferred
Federal	399			(262		)
State	58			(38		)
Total deferred	457			(300		)
Total income tax expense (benefit)	$	58		$	(502	)

The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate is as follows for the three months ended March 31, 2013 and 2012 (in thousands):



	Three Months Ended March 31,
	2013			2012
Tax benefit at statutory rate	$	(2,594	)	$	(884	)
State tax benefit, net of Federal taxes	(47		)	(103		)
Change in tax contingencies	(512		)	6
Valuation allowance changes affecting income tax expense	2,818			430
Transaction related costs	236			—
Officers compensation and other	157			49
Income tax expense (benefit)	$	58		$	(502	)

Components of income tax [Table Text Block]

The Company’s Federal and state income tax expense (benefit) from continuing operations is summarized in the following table (in thousands):



	Three Months Ended March 31,
	2013			2012
Current
Federal	$	(519	)	$	(29	)
State	120			(173		)
Total Current	(399		)	(202		)
Deferred
Federal	399			(262		)
State	58			(38		)
Total deferred	457			(300		)
Total income tax expense (benefit)	$	58		$	(502	)

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate is as follows for the three months ended March 31, 2013 and 2012 (in thousands):



	Three Months Ended March 31,
	2013			2012
Tax benefit at statutory rate	$	(2,594	)	$	(884	)
State tax benefit, net of Federal taxes	(47		)	(103		)
Change in tax contingencies	(512		)	6
Valuation allowance changes affecting income tax expense	2,818			430
Transaction related costs	236			—
Officers compensation and other	157			49
Income tax expense (benefit)	$	58		$	(502	)

- Definition

+ References

+ Details

EARNINGS PER SHARE (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2013 USD ($) $ / shares $ / warrant shares	Mar. 31, 2012 USD ($) $ / shares shares
Earnings Per Share [Abstract]
Antidilutive warrants excluded from computation of earnings per share, amount \| shares	3,400	0
Numerator:
Loss from continuing operations, net of income taxes \| $	$ (7,470)	$ (2,023)
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest \| $	(658)	(680)
Net loss \| $	$ (8,128)	$ (2,703)
Denominator - Basic:
Weighted Average Number of Shares Outstanding, Basic \| shares	57,047	55,307
Income (Loss) from Continuing Operations, Per Basic Share	$ (0.13)	$ (0.04)
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share	(0.01)	(0.01)
Earnings Per Share, Basic	$ (0.14)	$ (0.05)
Denominator - Diluted:
Common share equivalents of outstanding stock options and restricted awards \| shares	0	0
Weighted Average Number of Shares Outstanding, Diluted \| shares	57,047	55,307
Income (Loss) from Continuing Operations, Per Diluted Share	$ (0.13)	$ (0.04)
Income (Loss) from Discontinued Operations, Net of Tax, Per Diluted Share	(0.01)	(0.01)
Earnings Per Share, Diluted	$ (0.14)	$ (0.05)
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant	10
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount \| shares	6,500	6,900

BUSINESS COMBINATIONS (Details)	3 Months Ended		12 Months Ended
BUSINESS COMBINATIONS (Details)	Mar. 31, 2013 USD ($) $ / shares	Mar. 31, 2012 USD ($) $ / shares	Dec. 31, 2012 USD ($)	Feb. 01, 2013	Feb. 01, 2013 USD ($)	Feb. 01, 2013 yr	Jul. 31, 2012 USD ($) mo
Business Acquisition [Line Items]
Revenues	$ 199,071,000	$ 155,633,000
Income (Loss) from Continuing Operations Attributable to Parent	(7,470,000)	(2,023,000)
Business Combination, Description [Abstract]
Business Acquisition, Purchase Price Adjustment, Working Capital					$ 2,300,000
Number of customers				15,000
Assets Acquired and Liabilities Assumed [Abstract]
Identifiable intangible assets(a)	19,364,000	17,446,000	$ 17,446,000
Goodwill	414,234,000		$ 350,810,000
Income tax expense (benefit)	58,000	(502,000)
Amortization of Intangible Assets	2,082,000	879,000
All current acquirees [Member]
Business Acquisition [Line Items]
Revenues	205,163,000	182,458,000
Total net income (loss)	$ (4,815,000)	$ (3,917,000)
Basic income (loss) per share \| $ / shares	$ (0.08)	$ (0.07)
Diluted income (loss) per share \| $ / shares	$ (0.08)	$ (0.07)
Assets Acquired and Liabilities Assumed [Abstract]
Income tax expense (benefit)	$ (117,000)	$ (479,000)
Amortization of Intangible Assets	$ (495,000)	1,304,000
InfuScience, Inc. [Member]
Business Acquisition [Line Items]
Finite-Lived Customer Relationships, Gross							$ 400,000
Finite-Lived Intangible Asset, Useful Life	5 months
Business Acquisition, Purchase Price Allocation, Current Assets, Cash and Cash Equivalents							23,000
Interest expense elimination	$ 292,000	$ 1,063,000
Revenues	11,400,000
Income (Loss) from Continuing Operations Attributable to Parent	1,000,000
Business Acquisition, Cost of Acquired Entity, Total Potential Cash Paid depending on results							$ 41,400,000
Business Combination, Acquisition Related Costs	100,000
Business Combination, Description [Abstract]
Business Acquisition, Percentage of Voting Interests Acquired							100.00%
Business combination, contingent consideration period \| mo							24
Number of locations							5
Assets Acquired and Liabilities Assumed [Abstract]
Business Acquisition, Contingent Consideration, at Fair Value	3,100,000
Accounts receivable							$ 4,938,000
Inventories							586,000
Other current assets							371,000
Property and equipment							751,000
Identifiable intangible assets(a)							400,000
Other non-current assets							349,000
Current liabilities							(4,428,000)
Total identifiable net assets							2,990,000
Goodwill							38,429,000
Total fair value of consideration transferred							38,300,000
Business Combination, Consideration Transferred							$ 41,419,000
HomeChoice Partners, Inc. [Member]
Business Acquisition [Line Items]
Revenues	10,800,000
Income (Loss) from Continuing Operations Attributable to Parent	800,000
Business Combination, Acquisition Related Costs	800,000
Business Combination, Description [Abstract]
Business Acquisition, Percentage of Voting Interests Acquired				100.00%
Business Acquisition, Cost of Acquired Entity, Initial Purchase Price					70,000,000
Business Acquisition, Contingent Consideration, Potential Cash Payment					20,000,000
Business combination, contingent consideration period				2		2
Number of locations				14
Assets Acquired and Liabilities Assumed [Abstract]
Business Acquisition, Contingent Consideration, at Fair Value	8,000,000
Business Acquisition, Contingent Consideration, at Fair Value, Current	4,000,000
Business Acquisition, Contingent Consideration, at Fair Value, Noncurrent	$ 4,000,000
Accounts receivable					12,498,000
Inventories					1,984,000
Other current assets					154,000
Property and equipment					2,864,000
Identifiable intangible assets(a)					4,000,000
Other non-current assets					30,000
Current liabilities					(4,624,000)
Total identifiable net assets					16,906,000
Goodwill					63,419,000
Business Combination, Consideration Transferred					80,325,000
Minimum [Member] \| HomeChoice Partners, Inc. [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 months
Maximum [Member] \| HomeChoice Partners, Inc. [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Customer Relationships [Member] \| HomeChoice Partners, Inc. [Member]
Business Acquisition [Line Items]
Finite-Lived Customer Relationships, Gross					2,000,000
Customer Relationships [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 months		6 months
Customer Relationships [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years		3 years
infustion trademarks [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life			3 years
infustion trademarks [Member] \| HomeChoice Partners, Inc. [Member]
Business Acquisition [Line Items]
Finite-Lived Customer Relationships, Gross					1,000,000
Finite-Lived Intangible Asset, Useful Life	23 months
infustion trademarks [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	23 months
infustion trademarks [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Noncompete Agreements [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year
Noncompete Agreements [Member] \| HomeChoice Partners, Inc. [Member]
Business Acquisition [Line Items]
Finite-Lived Customer Relationships, Gross					$ 1,000,000
Finite-Lived Intangible Asset, Useful Life	1 year

DISCONTINUED OPERATIONS (Details) $ in Thousands	3 Months Ended		12 Months Ended
DISCONTINUED OPERATIONS (Details) $ in Thousands	Mar. 31, 2013 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2012 USD ($)	May 04, 2012 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Proceeds			$ 173,800
One time costs related to pharmacy services asset sale reserve	$ 132		134
total purchase price at closing, including the value of inventories on hand attributable to the operations subject to the Pharmacy Services Asset Sale.	158,800
Amount the company may be required to refund related directly or indirectly to the Buyers' retention of certain business after the closing	6,400
Contingent consideration, period				14 months
Accounts receivable and working capital liabilities relating to the operations subject to the Pharmacy Services Asset Sale	1,300
Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax	101,600
Amount the company received as the result of an agreement which provided that BioScrip ceased to be the sole fulfillment pharmacy for customers who came through the drugstore.com website		$ 3,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		2,900
Disposal Group, Including Discontinued Operation, Interest Expense		700
Revenue	(20)	338,103
Inventory				$ 30,560
Prepaid expenses and other current assets	43		134	299
Total current assets				30,859
Property and equipment, net				1,592
Goodwill				11,754
Intangible assets, net				2,503
Gross profit	(68)	22,960
Disposal Group, Including Discontinued Operation, Operating Expense	619	22,916
Loss from discontinued operations, net of income taxes	(658)	$ (680)
Accrued expenses and other current liabilities	37,580		41,491
Assets of Disposal Group, Including Discontinued Operation				$ 46,708
one time costs related to pharmacy services asset sale reserve, settled in cash	$ (2)
community pharmacy [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of locations				27
certain assets	3
mail order [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of locations				3
locations not tranferred as part of sale				2
Employee Severance [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
One time costs related to pharmacy services asset sale reserve	$ 43		45
one time costs related to pharmacy services asset sale reserve, settled in cash	(2)
Other [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
One time costs related to pharmacy services asset sale reserve	89		$ 89
one time costs related to pharmacy services asset sale reserve, settled in cash	$ 0

GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Feb. 01, 2013
intangible assets, line items [Line Items]
Amortization of Intangible Assets	$ 2,082	$ 879
indefinite lived intangible assets, gross	15,400	15,400
Indefinite-Lived Intangible Assets (Excluding Goodwill)	15,400	15,400
indefinite lived intangible assets accumulated amortization	0	0
Finite-Lived Intangible Assets, Gross	15,900	11,900
Finite-Lived Intangible Assets, Accumulated Amortization	(11,936)	(9,854)
Finite-Lived Intangible Assets, Net	3,964	2,046
intangible assets, gross	31,300	27,300
intangible assets, accumulated amortization	(11,936)	(9,854)
Intangible Assets, Net (Excluding Goodwill)	19,364	17,446	$ 17,446
Future Amortization Expense, Remainder of Fiscal Year	2,664
Future Amortization Expense, Year One	939
Amortization expense, year 2 and beyond	361
certificates of need [Member]
intangible assets, line items [Line Items]
indefinite lived intangible assets, gross	9,600	9,600
Indefinite-Lived Intangible Assets (Excluding Goodwill)	9,600	9,600
indefinite lived intangible assets accumulated amortization	0	0
nursing trademark [Member]
intangible assets, line items [Line Items]
indefinite lived intangible assets, gross	5,800	5,800
Indefinite-Lived Intangible Assets (Excluding Goodwill)	5,800	5,800
indefinite lived intangible assets accumulated amortization	0	0
Customer Lists [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Assets, Net		1,853
infustion trademarks [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Asset, Useful Life			3 years
Finite-Lived Intangible Assets, Gross	3,600	2,600
Finite-Lived Intangible Assets, Accumulated Amortization	(2,687)	(2,407)
Finite-Lived Intangible Assets, Net	913	193
Customer Relationships [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Assets, Gross	11,300	9,300
Finite-Lived Intangible Assets, Accumulated Amortization	(9,083)	$ (7,447)
Finite-Lived Intangible Assets, Net	$ 2,217
Noncompete Agreements [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year
Finite-Lived Intangible Assets, Gross	$ 1,000
Finite-Lived Intangible Assets, Accumulated Amortization	(166)
Finite-Lived Intangible Assets, Net	$ 834
HomeChoice Partners, Inc. [Member]
intangible assets, line items [Line Items]
Intangible Assets, Net (Excluding Goodwill)				$ 4,000
HomeChoice Partners, Inc. [Member] \| infustion trademarks [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Asset, Useful Life	23 months
HomeChoice Partners, Inc. [Member] \| Noncompete Agreements [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year
Minimum [Member] \| infustion trademarks [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Asset, Useful Life	23 months
Minimum [Member] \| Customer Relationships [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 months		6 months
Minimum [Member] \| HomeChoice Partners, Inc. [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 months
Maximum [Member] \| infustion trademarks [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Maximum [Member] \| Customer Relationships [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years		3 years
Maximum [Member] \| HomeChoice Partners, Inc. [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years

GOODWILL AND INTANGIBLE ASSETS Goodwill rollforward (Details) - USD ($) $ in Thousands	Mar. 31, 2013	Dec. 31, 2012
Goodwill [Line Items]
Goodwill	$ 414,234	$ 350,810
Infusion Services [Member]
Goodwill [Line Items]
Goodwill	367,706	304,282
Home Health Services [Member]
Goodwill [Line Items]
Goodwill	33,784	33,784
PBM Services [Member]
Goodwill [Line Items]
Goodwill	$ 12,744	$ 12,744

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 72
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-Clause 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph l
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

RESTRUCTURING AND OTHER EXPENSES RESTRUCTURING AND OTHER EXPENSES (Details) - USD ($) $ in Thousands	3 Months Ended		30 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Dec. 31, 2012
Restructuring Cost and Reserve [Line Items]
Transitional Expenses	$ 900	$ 100
Restructuring Charges	1,278	387
Phase I [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	(118)	300	$ 10,000
Restructuring Reserve, Settled with Cash			(31)
Restructuring Reserve	875		875	$ 1,024
Phase I [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	0		4,200
Restructuring Reserve, Settled with Cash			0
Restructuring Reserve	163		163	163
Phase I [Member] \| Consulting [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	(20)	$ 300	4,400
Restructuring Reserve, Settled with Cash			0
Restructuring Reserve	0		0	20
Phase I [Member] \| Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	(98)		1,400
Restructuring Reserve, Settled with Cash			(31)
Restructuring Reserve	712		712	841
Phase II [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	474		2,400
Restructuring Reserve, Settled with Cash	(514)
Restructuring Reserve	664		664	704
Phase II [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	382		1,500
Restructuring Reserve, Settled with Cash	(296)
Restructuring Reserve	645		645	559
Phase II [Member] \| Consulting [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	19		300
Restructuring Reserve, Settled with Cash	(145)
Restructuring Reserve	19		19	145
Phase II [Member] \| other restructuring costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	73		600
Restructuring Reserve, Settled with Cash	(73)
Restructuring Reserve	$ 0		$ 0	$ 0

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	3 Months Ended
PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Computer and office equipment, including equipment acquired under capital leases	$ 14,976		$ 14,443
Depreciation	2,459	$ 1,931
Capitalized Computer Software, Amortization	400	$ 700
Software capitalized for internal use	9,939		9,939
Vehicles, including equipment acquired under capital leases	1,630		1,540
Medical equipment	17,627		16,466
Work in progress	7,178		4,315
Furniture and fixtures	3,539		3,219
Leasehold improvements	8,383		7,164
Property, Plant and Equipment, Gross	63,272		57,086
Less: Accumulated depreciation	(35,505)		(33,365)
Property and equipment, net	$ 27,767		$ 23,721

DEBT (Details) - USD ($) $ in Thousands	Mar. 31, 2013	Dec. 31, 2012	Jul. 03, 2012	Jun. 30, 2012
Debt Instrument [Line Items]
Revolving credit facility	$ 27,053
Senior unsecured notes	225,000
Capital leases	1,311
long term debt and capital lease obligations, total	253,364
Long-term Debt and Capital Lease Obligations, Current	27,992	$ 953
Long-term Debt and Capital Lease Obligations	225,372	$ 225,426
Senior notes, fair value disclosure	$ 246,400
second amendment [Member]
Debt Instrument [Line Items]
line of credit libor floor				1.00%
Line of Credit Facility, Maximum Borrowing Capacity				$ 150,000
Third Amendment [Member]
Debt Instrument [Line Items]
line of credit libor floor			1.25%
Line of Credit Facility, Maximum Borrowing Capacity			$ 125,000
basket limitation for loans and advances to third parties and investments in permitted joint ventures			$ 60,000

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2013
future minimum payments due [Line Items]
Operating Leases, Future Minimum Payments Due, Current	$ 5,436
Capital Leases, Future Minimum Payments Due, Current	185
future minimum payments due, current	5,621
Operating Leases, Future Minimum Payments, Due in Two Years	6,535
Capital Leases, Future Minimum Payments Due in Two Years	225
future minimum payments due in two years	6,760
Operating Leases, Future Minimum Payments, Due in Three Years	5,481
Capital Leases, Future Minimum Payments Due in Three Years	192
future minimum payments due in three years	5,673
Operating Leases, Future Minimum Payments, Due in Four Years	4,518
Capital Leases, Future Minimum Payments Due in Four Years	23
future minimum payments due in four years	4,541
Operating Leases, Future Minimum Payments, Due in Five Years	3,815
Capital Leases, Future Minimum Payments Due in Five Years	0
future minimum payments due in five years	3,815
Operating Leases, Future Minimum Payments, Due Thereafter	5,024
Capital Leases, Future Minimum Payments Due Thereafter	0
future minimum leases due thereafter	5,024
Operating Leases, Future Minimum Payments Due	30,809
Capital Leases, Future Minimum Payments Due	625
Operating Leases, Rent Expense	1,800	$ 1,500
Long-term Purchase Commitment, Amount			$ 27,700
future minimum payments due	$ 31,434
Minimum [Member]
future minimum payments due [Line Items]
capital lease interest rate	3.00%
Maximum [Member]
future minimum payments due [Line Items]
capital lease interest rate	7.00%

COMMITMENTS AND CONTINGENCIES Legal Settlement (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2012
Legal Settlements [Line Items]
Litigation Settlement, Expense		$ 0.8
Loss Contingency Accrual, Carrying Value, Provision	$ 2.3
Loss Contingency, Damages Sought, Value	$ 3.5
State
Legal Settlements [Line Items]
Payments for Legal Settlements		0.6
Federal Government [Member]
Legal Settlements [Line Items]
Payments for Legal Settlements		$ 4.4

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14557-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 11
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

COMMITMENTS AND CONTINGENCIES Legal Proceedings (Details) $ in Millions	3 Months Ended
	Mar. 31, 2013 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Loss Contingency, Damages Sought, Value	$ 3.5

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

+ Details

OPERATING AND REPORTABLE SEGMENTS (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenue	$ 199,071	$ 155,633
Adjusted EBITDA	19,397	14,961
Other Cost and Expense, Operating	(7,916)	(6,582)
Interest Expense	(6,478)	(6,569)
Income Tax Expense (Benefit)	(58)	502
Depreciation	(2,459)	(1,931)
Amortization of Intangible Assets	(2,082)	(879)
Share-based Compensation	(1,973)	(966)
Acquisition and integration expenses	(4,623)	(172)
Restructuring Charges	(1,278)	(387)
Loss from continuing operations, net of income taxes	(7,470)	(2,023)
Assets	665,714		$ 642,376
Infusion Services [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	150,024	106,803
Sales Revenue, Services, Other	4,353	2,250
Revenue	154,377	109,053
Adjusted EBITDA	12,315	7,783
Assets	523,857		438,623
Home Health Services [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Services, Other	17,942	16,711
Adjusted EBITDA	883	1,080
Assets	63,280		62,403
PBM Services [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Services, Other	26,752	29,869
Adjusted EBITDA	6,199	$ 6,098
Assets	30,909		36,354
Corporate [Member]
Segment Reporting Information [Line Items]
Assets	45,189		95,813
Assets associated with discontinued operations, not sold [Member]
Segment Reporting Information [Line Items]
Assets	$ 2,479		$ 9,183

CONCENTRATION OF RISK (Details)	3 Months Ended
CONCENTRATION OF RISK (Details)	Mar. 31, 2013	Mar. 31, 2012
Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration of Risk, Percentage	21.00%	16.00%
Product Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration of Risk, Percentage	17.00%	21.00%

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Mar. 31, 2013	Mar. 31, 2012
Income Tax Disclosure [Abstract]
Current Federal Tax Expense (Benefit)	$ (519)	$ (29)
Current State and Local Tax Expense (Benefit)	120	(173)
Current Income Tax Expense (Benefit)	(399)	(202)
Deferred Federal Income Tax Expense (Benefit)	399	(262)
Deferred State and Local Income Tax Expense (Benefit)	58	(38)
Deferred Income Tax Expense (Benefit)	457	(300)
Income Tax Expense (Benefit)	58	(502)
Tax benefit at statutory rate	(2,594)	(884)
State tax benefit, net of Federal taxes	(47)	(103)
Change in tax contingencies	(512)	6
Valuation allowance changes affecting income tax expense	2,818	430
Income Tax Reconciliation, Nondeductible Expense	236	0
Other	$ 157	$ 49

STOCK-BASED COMPENSATION (Details) - USD ($) $ in Millions	3 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($) $ in Millions	Mar. 31, 2013	Mar. 31, 2012
All Share-Based Payment Plans [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock or Unit Option Plan Expense	$ 1.4	$ 0.7
Restricted Stock or Unit Expense	0.2	0.1
stock appreciation right expense	$ 0.4	$ 0.2
2008 Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation agreement by share-based payment awared, number of shares originally authorized	3,580,000
share-based compensation arrangement by share-based payment awared, adjustment to number of shares authorized	3,275,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,855,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	802,960
CHS 2006 Equity Incentive Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation agreement by share-based payment awared, number of shares originally authorized	13,000,000
BioScrip/CHS Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation agreement by share-based payment awared, number of shares originally authorized	3,106,315
rollover options	716,086
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,390,229
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,054,528

SHELF REGISTRATION STATEMENT (Details) $ in Millions	Mar. 18, 2013 USD ($) shares
SHELF REGISTRATION STATEMENT [Abstract]
Shelf registration, authorized proceeds \| $	$ 200
Shelf Registration, selling stockholders, saleable shares	12,682,831
Shelf Registration, selling stockholders, additional sellable shares upon exercise of warrants	3,400,945

SUBSEQUENT EVENTS (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	May 09, 2013	Apr. 24, 2013	Apr. 19, 2013	Apr. 16, 2013	Apr. 02, 2013	Mar. 31, 2013	Dec. 31, 2012
Employee Stock Purchase Plan [Abstract]
Common Stock, Par or Stated Value Per Share						$ 0.0001	$ 0.0001
Issuance of Equity [Member]
Stock Offering [Abstract]
Stock Issued During Period, Shares, New Issues	12,500,000
Stock Issued During Period, Shares, Selling Stockholders	3,125,000
Share Price		$ 12.00
Stock Issued During Period, Shares, Additional New Issues	1,875,000
Stock Issued During Period, Value, New Issues	$ 118.6
Refinancing of Debt [Member] \| Senior Unsecured Notes [Member]
Refinancing of Existing Indebtedness [Abstract]
Debt Instrument, Interest Rate, Stated Percentage						10.25%
Refinancing of Debt [Member] \| New Senior Secured Credit Facility [Member]
Refinancing of Existing Indebtedness [Abstract]
Debt Instrument, Face Amount				$ 325.0
Equity Method Investment, Disposal [Member]
Disposal of Investment in Variable Interest Entity [Abstract]
Payments for (Proceeds from) Investments	8.5
Escrow Amount			$ 1.1
Equity Method Investment Sold, Contingent Proceeds	$ 3.0
Employee Stock Purchase Plan [Member]
Disposal of Investment in Variable Interest Entity [Abstract]
Employee Stock Ownership Plan, Shares Registered					750,000
Employee Stock Purchase Plan [Abstract]
Common Stock, Par or Stated Value Per Share					$ 0.0001